England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy

First non-immunosuppressive dual-action therapy recommended by NICE for eligible patients with IgA nephropathy, a leading cause of kidney failure 1-3NICE's recommendation is based on clinically meaningful results from the phase-III PROTECT trial 4ST. GALLEN, Switzerland, May 23, 2025 /PRNewswire/ -- CSL Vifor is pleased to announce that the National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending that sparsentan can be used in the NHS in England as an option t ...